ABCG2 and non-small cell lung carcinoma: Yoh et al. reported that in advanced non-small cell lung cancer the response rate to chemotherapy in patients with ABCG2(−) tumors was 44%; however, in ABCG2(+) tumors, this rate decreased to 24%, accompanied by shorter overall survival than ABCG2(−) patients (p = 0.004) [28].